Reduced Survival with Higher Radiation Dose for Non-Hodgkin Lymphoma

Prior to hematopoietic stem cell transplant (HSCT), patients with non-Hodgkin lymphoma (NHL) typically undergo total body irradiation and chemotherapy as part of a conditioning regimen. In order to reduce the risk of relapse following HSCT, some patients with higher risk disease may receive higher doses of radiation. However, according to a study presented recently at […]

Read More

Atezolizumab and Bevacizumab Improve Quality of Life in HCC

While patients with unresectable hepatocellular carcinoma (HCC) have historically received first-line treatment with sorafenib, results from the IMbrave150 suggest that the combination of the PD-L1 inhibitor atezolizumab with the angiogenesis inhibitor bevacizumab may be a more effective treatment option. Initial results from this randomized, phase III trial (N = 501) showed a significant overall survival […]

Read More

conference news

Significant Activity for Tucatinib in Progressive Metastatic HER2-Positive Breast Cancer

At the 2019 San Antonio Breast Cancer Symposium (SABCS), Rashmi Murthy, MD (University of Texas MD Anderson Cancer Center, Houston, United States), presented results from the randomized phase III HER2CLIMB trial, which evaluated the addition of the HER2-targeting tyrosine kinase inhibitor (TKI) tucatinib to trastuzumab and capecitabine in 612 patients with progressive metastatic HER2-positive breast […]

Read More

Conference coverage

Capecitabine Improves Survival in Early-Stage Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is difficult to treat due to the lack of targetable receptors, and patients often have poor outcomes due to the lack of effective treatment options. At the 2019 San Antonio Breast Cancer Symposium (SABCS), Marion van Mackelenbergh, MD (University of Kiel, Germany), presented results from a subgroup of patients with early-stage […]

Read More

Blinatumomab More Effective than Chemotherapy in Relapsed ALL

Children as well as adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) who relapse following frontline therapy typically receive intensive chemotherapy followed by hematopoietic stem cell transplant (HSCT). Unfortunately, this treatment option is not always effective, and these patients tend to have poor outcomes. At the 2019 American Society of Hematology (ASH) […]

Read More

Carfilzomib Dara Combo Prolongs PFS in Relapsed/Refractory Multiple Myeloma

At the 2019 American Society for Hematology (ASH) Annual Meeting, Saad Usmani, MD, MBBS (Atrium Health, Charlotte, North Carolina, United States), presented results from the randomized phase III CANDOR trial, evaluating the combination of carfilzomib, dexamethasone, and daratumumab (KdD) for treatment of patients with relapsed/refractory multiple myeloma (Abstract LBA6). Patients (N = 466) who had […]

Read More

Predicting Six-Month Mortality Among Patients With Cancer

When physicians have conversations with their patients regarding advanced care early during treatment, it results in patients receiving care that is in line with their goals and wishes. While guidelines recommend conversations with high-risk patients regarding advanced care, many patients with cancer die without ever having had this conversation. Because oncologists are only able to […]

Read More

Olaparib Improves Outcomes in BRCA-Altered Castration-Resistant Prostate Cancer

Mutations in the DNA damage repair genes BRCA 1 and BRCA2 increase a tumor’s susceptibility to treatment with poly(ADP)ribose polymerase (PARP) inhibitors. This treatment approach is standard in breast and ovarian cancers, where these mutations commonly occur. Mutations in BRCA1/2 and the DNA damage repair gene ATM occur in as many as 30% of patients […]

Read More

CDK4/6 Inhibitors Demonstrate Consistent Survival Benefit in Breast Cancer

For patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, treatment with a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor in combination with endocrine therapy is a highly effective treatment option. Three CDK4/6 inhibitors are currently approved in the United States in this setting. At the ESMO Congress 2019, final results from the MONARCH 2 […]

Read More

Postsurgical Radiotherapy Not Necessary for Prostate Cancer

For men with early-stage prostate cancer, the standard of care for many years has been radical prostatectomy followed by adjuvant radiotherapy to prevent disease recurrence. However, the benefits of radiotherapy in this setting are not well documented and can be associated with numerous toxic effects. At the ESMO Congress 2019, results from a large clinical […]

Read More